Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel S Key

Showing results (111-120 of 255) with videos related to

Pageof 26
Sort By:
Blood|April 22, 2015
Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiencyBeth A Bouchard, John Chapin, Kathleen E Brummel-Ziedins, et al.
Blood Advances|December 22, 2020
Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohortPatrick Ellsworth, Sheh-Li Chen, Raj S Kasthuri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 20, 2013
Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patientsJason V Baker, Katherine Huppler Hullsiek, Robert L Bradford, et al.
Blood|September 17, 2005
The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory statesJian-Guo Wang, Shawn A Mahmud, Jacob A Thompson, et al.
Ejhaem|November 23, 2020
An exploratory study of the effects of strenuous exercise on markers of coagulation activation, circulating microparticles, and inflammation in sickle cell traitSarah Skinner, Eric D Ryan, Harry C Stafford, et al.
Blood|April 6, 2007
Sickle cell trait and the risk of venous thromboembolism among blacksHarland Austin, Nigel S Key, Jane M Benson, et al.
Thrombosis Research|October 27, 2009
Increased microparticle tissue factor activity in cancer patients with Venous ThromboembolismDavid A Manly, Jianguo Wang, Sam L Glover, et al.
Thrombosis and Haemostasis|November 6, 2009
Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogramKellie R Machlus, Emily A Colby, Jogin R Wu, et al.
Research and Practice in Thrombosis and Haemostasis|November 5, 2024
Periprocedural hemostatic prophylaxis and outcomes in bleeding disorder of unknown causeCallie Berkowitz, Alice Ma, Vanessa Miller, et al.
Thrombosis Research|July 17, 2013
Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancersAnubha Bharthuar, Alok A Khorana, Alan Hutson, et al.
Pageof 26

Showing results (111-120 of 255) with videos related to

Sort By:
Pageof 26
Blood|April 22, 2015
Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiencyBeth A Bouchard, John Chapin, Kathleen E Brummel-Ziedins, et al.
Blood Advances|December 22, 2020
Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohortPatrick Ellsworth, Sheh-Li Chen, Raj S Kasthuri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 20, 2013
Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patientsJason V Baker, Katherine Huppler Hullsiek, Robert L Bradford, et al.
Blood|September 17, 2005
The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory statesJian-Guo Wang, Shawn A Mahmud, Jacob A Thompson, et al.
Ejhaem|November 23, 2020
An exploratory study of the effects of strenuous exercise on markers of coagulation activation, circulating microparticles, and inflammation in sickle cell traitSarah Skinner, Eric D Ryan, Harry C Stafford, et al.
Blood|April 6, 2007
Sickle cell trait and the risk of venous thromboembolism among blacksHarland Austin, Nigel S Key, Jane M Benson, et al.
Thrombosis Research|October 27, 2009
Increased microparticle tissue factor activity in cancer patients with Venous ThromboembolismDavid A Manly, Jianguo Wang, Sam L Glover, et al.
Thrombosis and Haemostasis|November 6, 2009
Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogramKellie R Machlus, Emily A Colby, Jogin R Wu, et al.
Research and Practice in Thrombosis and Haemostasis|November 5, 2024
Periprocedural hemostatic prophylaxis and outcomes in bleeding disorder of unknown causeCallie Berkowitz, Alice Ma, Vanessa Miller, et al.
Thrombosis Research|July 17, 2013
Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancersAnubha Bharthuar, Alok A Khorana, Alan Hutson, et al.
Pageof 26